

Hemoperfusion

[View the current Hemoperfusion InDepth page on BioPortfolio.com](#) (PDF)

(<http://www.bioportfolio.com/indepth/Hemoperfusion.html>) - Regularly Updated.

Hemoperfusion is a medical process used to remove toxic substances from a patient's blood. The technique involves passing large volumes of blood over an adsorbent substance. The adsorbent substances most commonly used in hemoperfusion are resins and activated carbon. Hemoperfusion is an extracorporeal form of treatment because the blood is pumped through a device outside the patient's body. Its major uses include removing drugs or poisons from the blood in emergency situations, removing waste products from the blood in patients with renal failure, and as a supportive treatment for patients before and after liver transplantation. ([From the Wikipedia article Hemoperfusion](#).)



Recent Publications on Hemoperfusion:

- [Polymyxin B hemoperfusion and mortality in abdominal septic shock.](#)
BACKGROUND AND OBJECTIVES: Diarrhea-associated hemolytic uremic syndrome... 12th November, 2009
- JAMA. 2009 Nov 11;302(18):1969; author reply 1969-70. ([DOI Direct Link](#))
- [Polymyxin B hemoperfusion and mortality in abdominal septic shock.](#)
BACKGROUND AND OBJECTIVES: Diarrhea-associated hemolytic uremic syndrome... 12th November, 2009
- JAMA. 2009 Nov 11;302(18):1968; author reply 1969-70. ([DOI Direct Link](#))
- [Polymyxin B hemoperfusion and mortality in abdominal septic shock.](#)
BACKGROUND AND OBJECTIVES: Diarrhea-associated hemolytic uremic syndrome... 12th November, 2009
- JAMA. 2009 Nov 11;302(18):1968-9; author reply 1969-70. ([DOI Direct Link](#))
- [Hemoperfusion with polymyxin B-immobilized fiber column improves liver function after ischemia-reperfusion injury.](#)
AIM: To investigate the usefulness of direct hemoperfusion with a... 5th November, 2009
Department of Thoracic and Visceral Organ Surgery, Gunma University- *World J Gastroenterol.* 2009 Sep 28;15(36):4571-5.
- [Effect of charcoal hemoperfusion for removal of plasma methotrexate in a patient with acute renal failure.](#)
Strategies effective for accelerating methotrexate removal in delayed... 30th October, 2009
Department of Homeostatic Regulation and Development, Niigata University- *Pediatr Hematol Oncol.* 2009 Oct-Nov;26(7):520-5.
- [Intravenous paraquat poisoning.](#)
Paraquat is a substance that is highly poisonous to humans. Oral ingestion... 20th October, 2009
Department of Internal Medicine, Lotung Poh-Ai Hospital, Yi-Lan, Taiwan,- *J Chin Med Assoc.* 2009 Oct;72(10):547-50.

- [Effect of polymyxin B-immobilized fiber hemoperfusion on respiratory impairment, hepatocellular dysfunction, and leucopenia in a neonatal sepsis model.](#)
*PURPOSE: Sepsis and septic shock remain a major source of morbidity and...*6th October, 2009
Department of Pediatrics Surgery, Fujita Health University School of- *Pediatr Surg Int.* 2009 Oct 3. ([DOI Direct Link](#))
- [Intravenous lipid emulsions combine extracorporeal blood purification: A novel therapeutic strategy for severe organophosphate poisoning.](#)
*Organophosphorus (OP) pesticide self-poisoning is a major clinical problem...*30th September, 2009
Department of Intensive Care Unit, Tongji Hospital, Tongji Medical- *Med Hypotheses.* 2009 Sep 26. ([DOI Direct Link](#))
- [Multiply organ dysfunction syndrome due to tramadol intoxication alone.](#)
*Tramadol is a synthetic, centrally acting analgesic for the treatment of...*23rd September, 2009
Department of Emergency, Chao Yang Hospital, Capital Medical University,- *Am J Emerg Med.* 2009 Sep;27(7):903.e5-7. ([DOI Direct Link](#))
- [Extracorporeal elimination in acute valproic acid poisoning.](#)
*INTRODUCTION: Valproic acid (VPA) is an antiepileptic drug that is now...*26th August, 2009
National Poisons Information Service (Newcastle Unit), Regional Drugs and- *Clin Toxicol (Phila).* 2009 Aug;47(7):609-16. ([DOI Direct Link](#))
- [Successful treatment of crush syndrome complicated with multiple organ dysfunction syndrome using hybrid continuous renal replacement therapy.](#)
*BACKGROUND: The M8.1 'Wenchuan' earthquake occurred on May 12th 2008...*15th July, 2009
Department of Medicine, Division of Nephrology, West China Hospital,- *Blood Purif.* 2009;28(3):175-80. Epub 2009 Jul 8. ([DOI Direct Link](#))
- [\[Comparison of clinical efficacy between continuous veno-venous hemofiltration \(CVVH\) and CVVH combined with hemoperfusion for the treatment of multiple organ dysfunction syndrome\]](#)
*BACKGROUND: The M8.1 "Wenchuan" earthquake occurred on May 12th 2008...*3rd July, 2009
- *Zhongguo Wei Zhong Bing Ji Jiu Yi Xue.* 2009 Jun;21(6):373-4.
- [International differences in the treatment of sepsis: are they justified?](#)
*BACKGROUND: The M8.1 ""Wenchuan"" earthquake occurred on May 12th 2008...*26th June, 2009
- *JAMA.* 2009 Jun 17;301(23):2496-7. ([DOI Direct Link](#))
- [Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial.](#)
*CONTEXT: Polymyxin B fiber column is a medical device designed to reduce...*26th June, 2009
Department of Nephrology, Dialysis, and Transplantation, St Bortolo- *JAMA.* 2009 Jun 17;301(23):2445-52. ([DOI Direct Link](#))
- [Aconite poisoning.](#)
*INTRODUCTION: Aconitine and related alkaloids found in the Aconitum...*26th June, 2009
Department of Medicine and Therapeutics, The Chinese University of Hong- *Clin Toxicol (Phila).* 2009 Apr;47(4):279-85. ([DOI Direct Link](#))

BioNews Results for Hemoperfusion

- [Polymyxin B Hemoperfusion and Mortality in Abdominal Septic Shock](#)
Journal of the American Medical Association: Nov 10 2009 10:52PM Matching: hemoperfusion
- [Polymyxin B Hemoperfusion and Mortality in Abdominal Septic ShockReply](#)
Journal of the American Medical Association: Nov 10 2009 10:52PM Matching: hemoperfusion
- [A Longer Duration of Polymyxin B-Immobilized Fiber Column Hemoperfusion Improves Pulmonary Oxygenation in Patients With Septic Shock](#)
MDLinx: Oct 20 2009 10:52AM Matching: hemoperfusion



Hemoperfusion Patents:

- 7141716- [Inbred miniature swine and uses thereof](#)
- 7341843- [Botulinum toxin A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy](#)
- 7342083- [Polyamine polymers](#)
- 7348176- [Chamber with adjustable volume for cell culture and organ assist](#)
- 7374791- [Method for making and measuring a coating on the surface of a medical device using an ultraviolet laser](#)
- 7378569- [Transgenic pigs carrying both hHO-1 and hDAF transgenes for xenotransplantation](#)
- 7385012- [Polyamine polymers](#)
- 7408039- [Kits for treatment of hematologic disorders](#)
- 7429394- [Ion binding compositions](#)
- 7442546- [Method of modulating inflammatory response](#)
- 7442783- [Natural IgM antibodies and inhibitors thereof](#)
- 7335795- [Crosslinked amine polymers](#)
- 7332330- [Device for maintaining vascularization near an implant](#)
- 7326571- [Decellularized bone marrow extracellular matrix](#)
- 7169303- [Sorbent reactor for extracorporeal blood treatment systems, peritoneal dialysis systems, and other body fluid treatment systems](#)
- 7198785- [Systems and methods related to degradation of uremic toxins](#)
- 7279106- [Adsorbent and method for adsorbing a chemokine in body fluid](#)
- 7279175- [Stent coated with a sustained-release drug delivery and method for use thereof](#)
- 7283868- [Apparatus for sensing human prostate tumor](#)
- 7291122- [Hemofiltration methods for treatment of diseases in a mammal](#)
- 7294278- [Method for oxygenating wastewater](#)
- 7311845- [Adsorbing material for blood and plasma cleaning method and for albumin purification](#)
- 7312023- [Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood, generated as a result of extracorporeal blood processing](#)
- 7320757- [Body fluid processor enabling direct hemoperfusion](#)
- 7449605- [Crosslinked amine polymers](#)
- 7455771- [Means for removing protein-bound substances](#)
- 7556768- [Biocompatible devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood](#)
- 7556799- [Ion binding polymers and uses thereof](#)
- 7563613- [Detoxification and decontamination using nanotechnology therapy](#)
- 7575781- [Method for depositing a polymeric coating on a substrate](#)
- 7589238- [Treatment of hyperphosphatemia using crosslinked small molecule amine polymers](#)
- 7597677- [Wearable ultrafiltration device](#)
- 7601382- [Method of making a coated medical device](#)
- 7608674- [Pharmaceutical compositions comprising cross-linked small molecule amine polymers](#)
- 7611480- [Gastrointestinal bioreactor](#)
- 7611831- [Adsorbing pathogen-inactivating compounds with porous particles immobilized in a matrix](#)
- 7544673- [Coating compositions for bioactive agents](#)
- 7541048- [Coating compositions for bioactive agents](#)
- 7531179- [BoNT/A peptides and methods of predicting and reducing immunoresistance to botulinum](#)

[toxin therapy](#)

- 7459169- [Surface coating comprising bioactive compound](#)
- 7459305- [Ingestible gastrointestinal device](#)
- 7459502- [Pharmaceutical compositions comprising crosslinked polyamine polymers](#)
- 7462699- [BoNT/A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy](#)
- 7488495- [Ion binding polymers and uses thereof](#)
- 7494824- [Interactive system for presenting and eliminating substances](#)
- 7498023- [Blockade of T cell migration into epithelial GVHD target tissues as an approach to achieving anti-tumor effects against lymphohematopoietic malignancies without GVHD](#)
- 7517332- [Infusion device for medical fluids](#)
- 7520992- [Method and system for colloid exchange therapy](#)
- 7524420- [Method and system for colloid exchange therapy](#)
- 7615567- [Compounds and methods for promoting smoking cessation](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

